Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and... see more

TSXV:THRM - Post Discussion

Therma Bright Inc > Reasons I believe in THRM & AcuVid
View:
Post by Watchman21 on Apr 20, 2022 10:27am

Reasons I believe in THRM & AcuVid

UPDATING MY DD - In my opinion, here is why I believe AcuVid is assured to be granted FDA EUA

 

Clinical Studies

- AcuVid US Clinical Study:  

    - PPA 80.3% / NPA 98%. -    

    - US Sample Size: 230+ samples

 

- AcuVid Brazilian Clinical Study:  (If FDA accepted Diasorin’s International results, so should they accept AcuVid’s international results)

    - PPA 85.7% / NPA 97.8%.  

    - Brazil Sample Size: 260_ Samples

 

- AcuVid Blended Clinicals:  - 

    - PPA 83% / NPA. 97.9%. 

    - Total Sample Size:  490+ 

 

FDA EUA Clinical Studies

- US FDA EUA Requirements:  

    - PPA:  80.0% / NPA 95% Or Higher

 

Competition Clinicals Comparisons

- Abbott’s Binax NOW COVID 19 AG Test  (approved Dec 16, 2020) - 

    - PPA 84.6% / NPA 98.5%. - (long before Delta, Omicron and BA-2 Omicron). 

    - US Sample Size. 460

 

- Diasorin LIAISON SARS-CoV-2 Ag  (approve March 26, 2021)   - Combined US & European Clinical Results

    - PPA. 84.4% / NPA 99.5% (before Delta, Omicron and BA2 Stealth Omicron)

    - US & EUROPE sample Size:  399   ( 2 labs in US & 2 Labs in Europe)

 

Cross Reactivity Studies

- Cross Reactivity Studies - Nasal- borne viruses & bacteria (like all the other antigen tests). 

- ADDED Cross Reactivity Studies -  Mouth-borne viruses & bacteria

 

 

Alternative Rapid Testing Solutions Being Accepted for FDA EUA

CUE Health (https://www.cuehealth.com)  

FDA EUA. March 5, 2021.

Rapid Antigen Nasal Test

 

Detect (https://detect.com)…. 

FDA EUA.  October 29, 2021.

PCR Nasal Test

 

MicroGem PCR Saliva Test with Machine. (NOTE: 8+ other Saliva PCR Tests with FDA EUA)

FDA EUA - April 19, 2022. 

Machine: 10,000 Unites per year

Size:  33 pound machine 

Testing time:  30 minutes

Test per Machine per Day: 28 per day / 700 per month (25 days operating X 28 tests a day)

Machine Cost:  $8500

Cost Per Test: Machine cost is $12.14 first month, and then drops from there. PLUS the collection tube, buffer, pipette for sample collection is added, same items that make up AcuVid test…

Machine Test Process: 30 minutes / 1 at a time, over 14 hours a day

PCR-Type Test

 

INSPECT IR Breathalyzer Test

FDA EUA - April 14, 2022. 

Machine:  20 in stock, 100 per week production

Size:      Travel Suitcase Size

Testing Time:  3-5 minutes (including prep machine & patients)

Test Per Machine (14 hr day): 160 per day / 4000 per month (25 days operating X 160 tests a day)

Machine Lease:    $30000

Cost Per Test:    $7.50 per test

Machine Test Process: 3-5 minutes / 1 at a time, over 14 hour

PCR-Type Test

 

 

Challenges with InspectIR & MicroGEM Rapid Saliva PCR Test. 

- Limited Production Capabilities - no way any of these can produce 500K per week or service 500K people per week on machine production

- Testing Process:  1 person at a time per machine…not simultaneous like lateral flow cartridges. 

- Machine Cost $$$, Plus material costs (straws & nose clips, spit tubes, buffer solution, etc)

- Distribution:  requires huge distribution to service 500K people per week

 

AcuVid benefits

- Meets Standards:  Meets FDA EUA PPA and NPA results, cross reactivity tests & WHO Variants of Concern test

- Testing Process:   Can test a lot of people at same time, simultaneously 

- Affordable:  cost similar to other Covid-19 Rapid Antigen Nasal Test solutions

- Production:  Meets the November 2021 Guidance for 500K tests per week

Comment by Princetherma on Apr 20, 2022 10:41am
This post has been removed in accordance with Community Policy
Comment by hk1966 on Apr 20, 2022 1:56pm
If they were approved today this would have already leaked out to the market but more to the point there would be a market halt owing to fact this is significant market moving news
Comment by Princetherma on Apr 20, 2022 2:46pm
This post has been removed in accordance with Community Policy
Comment by burnout29 on Apr 20, 2022 4:36pm
the longer ,it takes for approval a dark cloud starts to cover this investment [ not good ]
Comment by birch1 on Apr 20, 2022 5:59pm
Oh God!  do you know how many people i know that have come down with COVID in the last few weeks and rapid tests are being used.....not over by any stretch.  LOL clown!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities